Result of EGM

By

Regulatory News | 26 Sep, 2024

Updated : 15:45

RNS Number : 8689F
Malin Corporation PLC
26 September 2024
 

Malin Corporation plc

 

Results of Extraordinary General Meeting

 

Dublin-Ireland, 26 September 2024: Malin Corporation plc (Euronext Growth Dublin:MLC) ("Malin", the "Company"), a company investing in highly innovative life sciences companies, today announces that the resolution proposed at its Extraordinary General Meeting (the "Resolution") held today in Dublin was passed.

 

The Resolution sought shareholder approval for the creation of additional distributable reserves in the Company by reducing the Company's existing share capital and to treat the reserves created at such reduction as distributable. The full text of the Resolution was included in the Notice of Extraordinary General Meeting of the Company circulated to shareholders on 27 August 2024 and made available on the Company's website.

 

A summary of the voting results is available on the Company's website www.malinplc.com.

 

The Company intends to promptly apply to the Irish High Court for confirmation of the Resolution, following which, if the High Court so approves, the share capital reduction as approved by shareholders will become effective (the "Share Capital Reduction"). The date of the hearing at which the High Court's confirmation of the Share Capital Reduction will be sought will be published on the Company's website, once it has been fixed by the High Court.

 

As previously announced, once the Share Capital Reduction is effective, the Company intends to proceed with a tender offer to return approximately €45 million to shareholders, which will require separate shareholder approval. Details of the tender offer will be announced in conjunction with the publication of a notice of an extraordinary general meeting and is in anticipated that the tender offer will take place in Q4 2024.

 

ENDS

 

 

 

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com  

 



 

For further information please contact:

Malin

Fiona Dunlevy, Executive Director/Company Secretary

Tel: +353 (0)1 901 5700

cosec@malinplc.com

 

Davy Corporate Finance (Euronext Growth Listing Sponsor & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

 

Sodali & Co (Media enquiries)         

Eavan Gannon

Tel: +353 87 236 5973                            

eavan.gannon@sodali.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMZZGZLDVLGDZM

Last news